| Autor: |
Ssuuna C; Rakai Health Sciences Program., Galiwango RM; Rakai Health Sciences Program., Kankaka EN; Rakai Health Sciences Program., Kagaayi J; Makerere University School of Public Health., Ndyanabo A; Rakai Health Sciences Program., Kigozi G; Rakai Health Sciences Program., Nakigozi G; Rakai Health Sciences Program., Lutalo T; Uganda Virus Research Institute., Ssekubugu R; Rakai Health Sciences Program., Wasswa JB; Rakai Health Sciences Program., Mayinja A; Rakai Health Sciences Program., Nakibuuka MC; Rakai Health Sciences Program., Jamiru S; Rakai Health Sciences Program., Oketch JB; Rakai Health Sciences Program., Muwanga E; Kyotera District Health Office, Ministry of Health., Chang LW; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD., Grabowski MK; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD., Wawer M; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD., Gray R; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD., Anderson M; Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, Illinois., Stec M; Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, Illinois., Cloherty G; Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, Illinois., Laeyendecker O; Division of Infectious Disease, Division of Medicine, Johns Hopkins School of Medicine, Baltimore, MD., Reynolds SJ; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Quinn TC; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Serwadda D; Makerere University School of Public Health. |
| Abstrakt: |
Background: Globally, key subpopulations such as healthcare workers (HCWs) have a higher risk of contracting SARS-CoV-2. In Uganda, limited access to personal protective equipment amidst lack of clarity on the extent and pattern of the community disease burden may exacerbate this situation. We assessed SARS-CoV-2 antibody seroprevalence among high-risk sub-populations in South-central Uganda, including HCWs, persons within the general population previously reporting experiencing key COVID-19 like symptoms (fever, cough, loss of taste and smell) and archived plasma specimens collected between October 2019 â€" 18 th March 2020, prior to confirmation of COVID-19 in Uganda. Methods: From November 2020 - January 2021, we collected venous blood from HCWs at selected health facilities in South-Central Uganda and from population-cohort participants who reported specific COVID-19 like symptoms in a prior phone-based survey conducted (between May to August 2020) during the first national lockdown. Pre-lockdown plasma collected (between October 2019 and March 18 th , 2020) from individuals considered high risk for SARS-CoV-2 infection was retrieved. Specimens were tested for antibodies to SARS-CoV-2 using the CoronaChek TM rapid COVID-19 IgM/IgG lateral flow test assay. IgM only positive samples were confirmed using a chemiluminescent microparticle immunoassay (CMIA) (Architect AdviseDx SARS-CoV-2 IgM) which targets the spike protein. SARS-CoV-2 exposure was defined as either confirmed IgM, both IgM and IgG or sole IgG positivity. Results: The seroprevalence of antibodies to SARS-CoV-2 in HCWs was 21.1% [95%CI: 18.2-24.2]. Of the phone-based survey participants, 11.9% [95%CI: 8.0-16.8] had antibodies to SARS-CoV-2. Among 636 pre-lockdown plasma specimens, 1.7% [95%CI: 0.9-3.1] were reactive. Conclusions: Findings suggest a high seroprevalence of antibodies to SARS-CoV-2 among HCWs and substantial exposure in persons presenting with specific COVID-19 like symptoms in the general population of South-central Uganda. Based on current limitations in serological test confirmation, it remains unclear whether pre-lockdown seropositivity implies prior SARS-CoV-2 exposure in Uganda. |
